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In the course of normal pregnancy intravascular volume is increased whereas sodium restriction is thought to reduce plasma volume and cardiac output. In the present study, we measured the effect of long-term severe sodium restriction on vasopressin (AVP) and oxytocin (OT) levels during normal pregnancy and after delivery.
Fifty-nine healthy nulliparous women were randomized either for a low sodium diet (20 mmol sodium daily) or for a normal diet from week 12 of pregnancy onwards.
Circulating plasma levels and urinary excretion of AVP and OT, their neurophysins (Np-AVP and Np-OT) and AVP bound to platelets were determined at regular intervals during pregnancy and after delivery. After completion of the study, women on a sodium-restricted diet were compared with control women on a normal diet using repeated measurement ANOVA with adjustment for potentially confounding variables.
After randomization, a reduction in urinary sodium excretion of, on average, 40\p=n-\82%was found. In general, no effect of sodium restriction could be demonstrated on the various parameters (0\m=.\53<P<0\m=.\98) with the exception of a significantly lower 24-h urinary AVP excretion by non-smokers with sodium restriction compared with non-smokers having a normal diet (P=0\m=.\018) For all parameters, clear changes were found in the course of Introduction Both the neurohypophysial hormones arginine vasopressin (AVP) and oxytocin (OT) are involved in volume regu¬ lation in human pregnancy (Whalley & Pritchard 1963 , Schrier 1988 ). In normal pregnancy, a 30-40% increase in plasma volume is found, possibly as a reaction to early vasodilation. Because of the vasodilatation, baroreceptor activation occurs, which might lead to non-osmotic AVP release (Schrier 1988) . However, the exact role of AVP and OT in volume expansion during pregnancy remains to be established and this work is hampered by difficulties in neuropeptide measurement leading to variations in reported plasma levels.
Sodium restriction during pregnancy is thought to reduce plasma volume (Brown 1988) and is considered to be an appropriate therapy in hypertensive pregnancy by some, on the assumption that hypertension is a conse¬ quence of salt retention and early volume expansion (Hamlyn & Mordecai 1986 ). On the other hand, a reduction of plasma volume is considered potentially dangerous for fetal well-being, especially (Jaspers et al. 1983) and is apparently well tolerated by mother and fetus (Steegers et al. 1991 (Davison et al. 1989 ). Immediate inactivation of CAP during blood sampling is mandatory for a reliable assay. Even with optimal inactivation of CAP, free AVP levels in pregnancy during normal hydration are around the detection limit of the assay (Davison et al. 1989 , Thornton et al. 1990 , van der Post et al. 1994 ) and therefore subject to large assay variation. More information about OT and AVP metabolism can be obtained by measuring prohormone products. The precursor molecules of AVP and OT, neurophysin-vasopressin (Np-AVP) and neurophysin-oxytocin (Np-OT), are metabolized more slowly (Lauson 1974 (Fuchs et al. 1991 ) is bypassed in this way. Finally, plateletassociated AVP is reported to change as a result of chronic osmotic and non-osmotic stimuli (Preibisz et al. 1983 , Bichet et al. 1986 ), like reduced cardiac output, in non-pregnant subjects. In third trimester pregnancy, platelet-associated AVP levels are two to five times higher than free circulating AVP levels (van der Post et al. 1993 
Subjects and Methods

Patients
All patients participated in a multicentred study (Steegers et al. 1991 , van Buul et al. 1995 . Some data from subgroups of the current study population have contrib¬ uted to previous publications (van Buul et al. 1995 
Study protocol
The study protocol has been described previously (Steegers et al. 1991) . Briefly, at 13, 16, 20, 24, 28, 32 AVP, vasotocin and desamino-D-AVP was below 0-01%.
The detection limit, defined as B/B" < 90%, was 0-25 pg/ tube for AVP and 0T25 pg/tube for OT. Intra-assay coefficient of variation (C.V.) was 9-1%, and the interassay C.V. in ten different assays was 13-4%. Recovery of 3-2 pg AVP/OT per ml added to whole blood of 22 pregnant women and nine non-pregnant controls was 57% and 59%
and from plasma 76% and 80% respectively. In plasma from pregnant women, kept at 20°C for several minutes without CAP inhibitors, AVP levels were equal to the detection limit. Platelet-bound AVP was defined as the difference between PRP and PPP values corrected for the number of platelets. The detection limit of our platelet-associated AVP assay in this study was 0-6 pg/ml, which corresponds to approximately 0-24 pg/10 platelets (see Fig. 2 ).
Np-AVP and Np-OT assays were performed at the Neuroendocrinology Section, CHU Sart Tilman, Université de Liège, Belgium (Legros & Franchimont 1972 , Pulían et al. 1979 . Briefly, plasma samples were obtained after centrifugation of 10 ml venous blood with EDTA (3 mmol/1). Small aliquots of plasma were stored at -20°C until analysis. Direct assays were performed in 100 µ plasma volumes. For Np-AVP, the detection limit was 0 2 ng/ml and the intra-and interassay variations were 6 and 10-7% respectively. Np-OT was defined as total neurophysin immunoreactivity minus Np-AVP levels. Detection limit and assay variation of total neuro¬ physin immunoreactivity were 0-2 ng/ml and 6-1% respectively.
Urinary analysis for AVP and OT Isoelectric focusing (IEF) was performed using thin largepore polyacrylamide gels. Urine samples (10 ml Figure 1 shows the 24-h sodium excretion and sodium/ creatinine ratio after randomization ('intention to treat', n=48) as well as after correction for dietary failure ('com¬ pliant to diet', n=39). The average urinary sodium excre¬ tion during dietary sodium restriction (113-251 days gestational age) was 80-9 (s.d. 83-9) mmol/24 h and 133 (s.d. 42-9) mmol/24 h for women without sodium restric¬ tion, while the sodium/creatinine ratio averaged (s.d. 6-89) and 13-7 (s.d. 4-3) respectively. This means that a mean reduction of 40% in sodium excretion was obtained by the prescription of sodium restriction. In the 'compliant to diet' group, the reduction amounted to 82%, with an average sodium excretion of 28-8 (s.d. 33-8) mmol/24 h and a sodium/creatinine ratio of 2-5 (s.d. 2-4).
The differences between the diet groups in sodium excretion in both analyses were highly significant during significantly between the low sodium and normal diet groups; levels increased significantly after pregnancy: mean differences between pre-and postpartum values were osmolality, 9 mosmol/kg ( <0 001), sodium, 3-2 mmol/1 ( <0 001) and potassium, 0-27 mmol/1 (P<0-0001).
Of the 48 women followed until postpartum, four developed hypertension (8%).
There were no significant differences in birthweight between the diet groups. No perinatal deaths occurred nor were neonates born with major or minor handicaps.
AVP and OT excretion: effects of salt restriction (see Table 2 ) There appeared to be no overall differences nor timespecific differences between the two groups for any of the measured parameters, not even after correction for dietary failure. However, a statistically significant difference in 24-h urinary AVP excretion was found during sodium restriction when adjusted for smoking. In non-smoking women, sodium restriction resulted in a significantly lower AVP excretion (P<O018, see Table 2 ) from day 196 onwards. Urinary OT excretion was below the detection limit of 1-6 pg/ml, which equals about 2-4 ng/24 h. After correction for dietary failure ('compliant to diet' analysis) the 13 women with salt restriction appeared to have lower platelet-bound AVP values at 141 days but higher levels at Figure 1 (a and c) 24-h sodium excretion and (fa and d) sodium/creatinine ratio for women randomized for severe sodium-restricted diets (crossed boxes) or normal diets (solid boxes), (a and fa) 'Intention' means data for randomized women who completed the study (n=48, 22 salt-restricted), (c and d) 'actual diet' means data after excluding women who stopped sodium-restricted diets (n=39, 13 salt-restricted). Values are means with s.e.m. During sodium restriction, differences in sodium excretion were highly significant ('intention' P=00023, 'actual' P<0-0001). No significant differences existed before randomization (P=0-29) and postpartum (P=0-25). The shaded area represents the perinatal period.
168 days gestational age. Even so, Np-OT was lower at 113 days but higher at 251 days gestational age.
Patients with high peptide levels at the beginning of pregnancy tended to have high levels later on: peptide levels measured before randomization significantly deter¬ mined levels later in pregnancy after randomization (P=0-04 to P<0-001), except for 24-h urinary AVP (P=0-26) and free AVP plasma levels (P=0-67).
Apart from the effect on urinary AVP excretion, smoking had no further effect on circulating peptide levels. Hypertension influenced the time-course of platelet-bound AVP values; there was a decrease only at 113 days gestational age (P=0-003).
AVP and OT levels: effects ofpregnancy (see Fig. 2 Although women who actually kept to their salt-restricted diets had indeed a huge reduction in sodium excretion (see Fig. 1 ) it was clearly difficult to keep to a severe sodium-restricted diet as the reduction in sodium excretion or sodium/creatinine ratio, on average, was less than 40% (see Fig. 1 ). From the 29 women allocated to sodium restriction, seven stopped the study and nine shifted early in pregnancy to a non-sodium-restricted diet, making a total of a 55% (16 out of 29) dropout. As this might lead to considerable selection bias, analysis was performed for the 'intention to treat' group («=48) as well as for the 'com¬ pliant to diet' group (n=39). Hereby, we corrected for non-compliance as well as selection bias. The two analyses revealed no differences in the results (see Table 2 ).
Because we could not find any differences between the diet groups in circulating AVP or Np-AVP plasma levels, (Brown 1988) or cardiac output during sodium restriction (Steegers et al. 1991 ) might normalize a dietaryinduced decrease in platelet-bound AVP, since nonosmotic stimuli like reduced cardiac output increase platelet-bound AVP in non-pregnant subjects (Preibisz et al. 1983) . It indicates that reduction in effective circu¬ lating volume during sodium restriction in pregnancy (Steegers et al. 1991) does not lead to non-osmotic AVP release. Interestingly, in the course of normal pregnancy, we even found a gradual decrease in platelet-bound AVP levels (see Fig. 2 ), which contradicts any underfilling hypothesis of pregnancy (Schrier 1988) . The steadily reduced circulating platelet-bound AVP levels found during the course of pregnancy might indeed reflect the increase in blood volume during pregnancy. Decreased peptide platelet binding has also been described for All (Baker et al. 1990) (1988, 1989) and are very near to the detection limit of the AVP assay of 0-6 pg/ml plasma. The same holds for OT with its detection limit in our assay of 0-6 pg/ml plasma (see also Fig. 2 ). Increased MCR of AVP (Davison et al. 1989) probably accounts for the lower plasma AVP levels during pregnancy compared with after delivery. This is in spite of increased Np-AVP levels during pregnancy which indicate increased release. This is in agreement with activation of the neurosecretory nuclei in the rat brain during pregnancy (Swaab & Jongkind 1970) . From these data it might be concluded that in fact there is increased release of AVP leading to elevated Np-AVP levels but, because of the increased MCR of the circulating peptide, AVP levels are decreased.
The basal OT plasma levels (Fig. 2) (Thornton et al. 1992 ). In addition, Amico & Hempel (1990) and OT ( =0·99) were not different between women who were breastfeeding and those who were not, although Np-OT values in breastfeeding mothers tended to be higher. Median (range) plasma Np-OT values in mothers who were breastfeeding compared with those who were not were 1-3 ng/ml (0-7-5-5) vs 0-6 (0-55-0-95). Finally, one must consider the possibility that increased Np-OT is of uterine origin as can be inferred from studies by Chibbar et al. (1993) .
We could not demonstrate an effect of hypertension on any of the parameters measured. About 5-10% of the women enrolled in the study were expected to develop hypertension. In our study group, four women developed hypertension (8%), which is too low a number to enable any conclusion to be drawn. On the other hand, an earlier study did not support a role for AVP in pregnancy-induced hypertension (van der Post et al. 1993 ).
In conclusion, this study provides evidence for de¬ creased renal AVP excretion during chronic severe sodium restriction in human pregnancy without a significant change in circulating AVP and OT levels or plateletbound AVP, despite the known decrease in circulating volume. No evidence was found for non-osmotic AVP release during pregnancy or chronic dietary sodium restriction.
